Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability study of deuteriumremidvir hydrobromide suspension in healthy adults
NCT06749236Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Aug 2025
- Primary completion
- Aug 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deuteriumremidvir (2 arms), sponsored by Vigonvita Life Sciences. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Measurable Concentration at 48 hours and 1 more. Started Aug 2025; status: completed.
02
Drugs
deuteriumremidvir
Beyond the preview
Go deeper on NCT06749236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06749236.